Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in…

WATERTOWN, Mass., Jan. 30, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity as the first dedicated microbiome CDMO.

As Chief Operations Officer, Dave will be responsible for driving the continued growth of Arranta's operations, including the ongoing expansion of the company's Microbiome process development center of excellence in Gainesville, FL as well as operationalizing Arranta's new best-in-class GMP facility in Watertown, MA. He is an accomplished business leader with a demonstrated track record of success within the contract development and manufacturing services industry.

Dave brings over 20 years of broad operational and commercial experience in the CRO and CDMO sectors. Most recently, Dave served as the Senior Vice President & Head of AMRI's Drug Product business unit where he had responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Prior to that, Dave held roles of increasing responsibility at Aptuit and Charles River Laboratories in the UK, Italy and USA. Dave holds an MBA in strategy, finance and marketing from the University of Edinburgh and an undergraduate degree in Business.

Jason Rahal has over 25 years of experience in biotechnology. Prior to joining Arranta as SVP of Business Development, Jason was a member of the senior management team at Cobra Biologics, a CDMO providing ATMP services including Live Biotherapeutic Products (LBPs) with facilities in the United Kingdom and Sweden. Jason initially joined Cobra as VP Business Development in 2002, as the first US based employee to establish the company's presence in North America, he was promoted to SVP Business Development in 2006.

Prior to Cobra, Jason worked at Excell Biotech, a biologics CDMO based in Edinburgh, Scotland and Stratagene Cloning Systems based in La Jolla, CA in various business development and sales positions. Jason has a strong background in molecular and cell biology, beginning his career at Northwestern University in Evanston, IL managing a molecular endocrinology laboratory with several peer reviewed publications. Jason holds a BA in Biology and Studio Art from Knox College.

"I am delighted to have two experienced leaders join Arranta Bio's senior team as we continue to build out our organization and invest in facilities as the leading end-to-end dedicated CDMO supporting microbiome pioneers with our services" said Mark Bamforth, President & CEO of Arranta.

Almost 200 companies are actively exploring the linkage between diseases and the microbiome millions of bacteria, fungi, protozoa and viruses that live inside and on the human body in order to identify therapeutic targets. Scientists have called it the second genome, and in fact, the number of genes in the microbes making up one person's microbiome is estimated to be at least 200 times the number in the human genome.

Over the last decade, there has been rapid acceleration in scientific understanding of the composition and functions of the gut microbiota. Arranta is proud to be the leading CDMO focused on supporting the supply needs of these innovators.

About Arranta BioFounded in 2019, Arranta Bio is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize therapies targeting the human microbiome. Arranta Bio acquired CaptozymeTM the leader in process development and clinical contract manufacturing for microbiome pioneers whose experienced team has worked with and developed processes for over 125 different species spanning 80 different genera of live biotherapeutics since 2009. Headed by a management team and technical experts with a proven track record in both process development and contract manufacturing through fermentation to lyophilization and encapsulation of live biopharmaceuticals, Arranta offers the knowledge and resources necessary to help clients develop and manufacture promising new microbiome therapies to meet the needs of patients. Additional information about Arranta is available at http://www.arrantabio.com. Enquiries can be sent to info@arrantabio.com

About Ampersand Capital PartnersFounded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at http://www.ampersandcapital.com

Arranta Bio Media contact: Guy TieneThat's Nice LLCT: +1 212 366 4455E: guy@thatsnice.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/arranta-bio-announces-key-leadership-additions-of-chief-operations-officer-and-svp-of-business-development-as-it-commits-to-a-100m-investment-in-building-end-to-end-microbiome-capacity-300995736.html

SOURCE Arranta Bio

Read more:
Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in...

Cancer cure: Collaboration between Ervaxx and Cardiff University to develop T-cell immunotherapy treatment – EconoTimes

The coronavirus has everyone on high alert, but scientists have not forgotten about the existing diseases that have yet to have a cure, such as cancer. A new partnership between Cardiff University and biotechnology company Ervaxx was announced in order to develop the T-cell immunotherapy treatment further.

As announced on the Ervaxx site, the two institutions will collaborate in the development of a potential cure in the form of utilizing Dark Antigens to which the company is known for, in order to develop T-cell receptor-based immunotherapy treatments for cancer. Ervaxx will be funding the program. The partnership between the two groups will help bring forward the findings Professor Andrew Sewell and his team have documented.

They were able to identify a T-cell clone that can target and kill many types of cancer cells while keeping the healthy cells intact. This T-cell clone targets an MHC class-1-related protein named MR1, which is a cancer-specific ligand. This breakthrough may provide a universal cancer cure and change the game into the concept of immunotherapy as a treatment for the disease.

As part of the collaboration, Ervaxx will have exclusive access to the patents at Cardiff University that claim T-cells and T-cell receptors reacting to cancer-specific antigens. On the universitys side, Professor Sewell said, This collaboration will use our world-class expertise in T-cell biology to identify T-cells and TCRs reactive to those targets and pave the way for a new wave of treatments in cancer and potentially other areas,

Although this type of treatment for cancer has already been discovered years back, what makes this significant is that this method is slowly becoming accessible to more parts of the world. As pharmaceutical giants, while they may offer this type of treatment, the accessibility is very limited. Therapies like TCR-T and CAR-T, which also make use of a patients T-cells, which are genetically modified to kill the cancerous cells and re-introduced into the body are already existing. However, the disadvantage of these treatments is that it targets certain types of blood cancer and has not been successful when it comes to tumors.

Professor Sewell stated regarding their discovery, Not only would the treatment work for most types of cancer, but the same approach could be applied in all patients.

Read the original:
Cancer cure: Collaboration between Ervaxx and Cardiff University to develop T-cell immunotherapy treatment - EconoTimes

Aparna Bhaduri – The Conversation US

Profile Articles Activity

Aparna Bhaduri earned a B.S in Biochemistry and Cell Biology and a B.A in Political Science from Rice University in 2010. She completed her doctoral studies at Stanford University in Cancer Biology in 2016, where she focused on epithelial tissue differentiation and neoplasms She is currently a postdoctoral scholar at the University of California San Francisco in the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, in the lab of Dr. Arnold Kriegstein. As a postdoctoral scholar, she has used single-cell RNA sequencing to characterize cell types in the developing cortex across cortical areas, in human and non-human primates, and in glioblastoma. Because experimental manipulations of the developing human cortex will require in vitro models, she has been using similar approaches to compare cells types in organoid models and primary tissues. Her long term interests are in understanding how stem cells during cortical development give rise to the human brain, and how aspects of these developmental programs can be hijacked in cancers such as glioblastoma. In order to explore these questions, Aparna uses single-cell genomics, informatic analysis, and organoid models.

See original here:
Aparna Bhaduri - The Conversation US

Talented Teacher – HSC Newsbeat

Angela Wandinger-Ness, PhD, professor in The University of New Mexico Department of Pathology, is being honored by the American Association for the Advancement of Science (AAAS) with its 2020 Lifetime Mentor Award.

She will receive the award, which recognizes her for mentoring some 270 scientists over her 29-year teaching career, at the associations annual meeting in Seattle on February 15.

Wandinger-Ness is both the associate director for education, training and mentoring and the Victor and Ruby Hansen Surface Endowed Professor in Cancer Cell Biology and Clinical Translation at the UNM Comprehensive Cancer Center.

I am deeply humbled by being nominated and receiving this award, she said, adding that she is especially moved to know that she was nominated for the award by people she trained and mentored who are now respected scientists in their own right.

Dr. Wandinger-Ness was an incredible mentor to me, providing personal and professional guidance throughout my time in her laboratory and beyond, wrote Mary-Pat Stein, professor of biology at California State University, Northridge, in a nominating letter to the AAAS.

The AAAS Mentor Award honors individuals who during their careers demonstrate extraordinary leadership to increase the participation of underrepresented groups in science and engineering fields and careers. These groups include women of all racial or ethnic groups African American, Native American and Hispanic men and people with disabilities.

Wandinger-Ness has twice been singled out by her colleagues at UNM for the annual Excellence in Research Award. In nominating her for the Teaching and Learning category in 2019, Cancer Center CEO Cheryl Willman, MD, hailed her unwavering commitment to scholarship in teaching and mentoring trainees at all levels of learning.

Willman added, Dr. Wandinger-Ness is a devoted and compassionate research mentor who invests her time to nurture and develop a more diverse scientific community and scientific leaders for our future.

Wandinger-Ness was elected a fellow of the AAAS in 2012. Her research has focused on GTPases, a family of enzymes that operate as molecular switches in many different cellular functions. She currently is looking for way to translate her work into potential therapies for ovarian cancer.

Wandinger-Ness joined the UNM faculty in 1998 after seven years at Northwestern University. Through the years, she mentored dozens of minority trainees, including 15 bachelors and masters students who went on to earn doctorate degrees, 26 PhD students and 53 postdoctoral fellows.

She was recruited to UNM by Mary Lipscomb, MD, then-chair of the Department of Pathology. She was an absolute 200% advocate for me, Wandinger-Ness says. She thought I walked on water, which I knew I didnt . . . that was the first time I felt that I understood what it meant to have somebody who gets you.

Wandinger-Ness, whose parents emigrated to the U.S. following World War II, recalls growing up feeling the animosity many people still held toward Germans.

I was assimilated, she says. Thats not true for a lot of people who come as immigrants. For me, it is deeply personal to train diverse trainees of every stripe to see that they should be welcome and part of this diverse community.

Excerpt from:
Talented Teacher - HSC Newsbeat

Neuroscientist John Ngai named director of NIH BRAIN Initiative – UC Berkeley

The National Institutes of Health (NIH) has picked long-time UC Berkeley neuroscientist John Ngai to head its BRAIN Initiative, a multibillion-dollar federal research push to develop new tools that will help scientists understand how the brain works and lead to new treatments for brain dysfunction.

The BRAIN Initiative aims to revolutionize our understanding of the brain and brain disorders, said NIH director Francis Collins today (Wednesday, Jan. 29) in announcing the appointment. We welcome Dr. Ngais leadership in steering this groundbreaking 21st century project.

As director of what formally is the NIH Brain Research through Advancing Innovative Neurotechnologies Initiative, Ngai will help steer about $500 million in research dollars this year to the most promising projects around the country. From 2014, when the first awards were given, through 2019, the initiative distributed $1.3 billion, and it is expected to disperse $5.2 billion by 2025.

In the first five years of the BRAIN Initiative, we have seen some remarkable advances in technologies for monitoring, as well as for perturbing activity in the brain, some of which have led to new innovations in treating patients with devices such as deep brain stimulators in the areas of epilepsy and Parkinsons disease, Ngai said. By continuing to develop new tools for understanding how the brain works, we hope to provide the basis for future clinical treatments.

Dr. Ngais appointment comes at a propitious time as the BRAIN Initiative enters a new and important phase, said Walter Koroshetz, director of NIHs National Institute of Neurological Disorders and Stroke (NINDS). Dr. Ngai will provide the initiative the clear vision the project needs to navigate through this critical period.

Ngai, the Coates Family Professor of Neuroscience at UC Berkeley, was a guest of the White House in 2013 when the initiative was first announced and together with nine Berkeley colleagues received one of the first NIH BRAIN Initiative grants to help classify cells in the brain. Over the past five years, the initiative has funded hundreds of research projects nationwide that have led to several breakthroughs, including the creation of systems for studying the circuits involved in generating behavior in animal models, the development of a computer program that can mimic natural speech from peoples brain signals and the construction of a brain cell parts list.

Most of the money comes from the annual budgets of 10 NIH institutes led by the NINDS and the National Institute of Mental Health (NIMH). Congress has appropriated additional funds each year since the passage of the 21st Century Cures Act in 2013.

Ngai will begin his new position in mid-March, overseeing the long-term strategy and day-to-day operations of the initiative with oversight by the directors of the 10 institutes participating in the BRAIN Initiative. He will retire from UC Berkeley as an emeritus professor and move his lab to new quarters in Bethesda, Maryland, home of the NIH.

Ngai first joined the UC Berkeley Department of Molecular and Cell Biology in 1993, after earning his Ph.D. in biology in 1987 from the California Institute of Technology and working as a postdoctoral fellow at Columbia University College of Physicians and Surgeons from 1988 until 1992. It was at Columbia, in the lab of future Nobel Laureate Richard Axel, that he initiated his studies of the bodys olfactory system: our sense of smell. At the time, it was one of the last of the five senses to be thoroughly studied, Ngai said, and he applied his training in molecular biology to unearthing the genes involved in receiving and processing information.

Neuroscientist John Ngai was appointed director of the NIH BRAIN Initiative. (UC Berkeley photo by Brittany Hosea-Small)

As new tools came along, he probed deeper and has in recent years employed the latest technology, single cell sequencing, to discover all the genes expressed in specific neurons. His latest interest is how the olfactory system repairs itself. As director of the Helen Wills Neuroscience Institute from 2011 to 2013, Ngai helped bring engineers and physical scientists into the institute to join biologists.

This was the vision that (former UC Berkeley professors) Corey Goodman and Carla Shatz had when they founded the institute in 1999, with the encouragement of then-Executive Vice Chancellor and Provost Carol Christ, now UC Berkeleys chancellor, Ngai said. To drive and accelerate the future of neuroscience requires the development of new tools and the incorporation of ideas from fields outside of biology. The BRAIN Initiative has enabled us to realize that vision in a grand way.

John has helped put UC Berkeley in the vanguard of the technology-centered approach that is the focus of the BRAIN Initiative, said Paul Alivisatos, UC Berkeleys vice chancellor and provost and one of the scientists who helped catalyze early discussions that laid the foundation for the initiative. This foresight to incorporate our unparalleled strengths in the physical and engineering sciences with our preeminence in neurobiology prepared Berkeley to leverage these new technologies five years ago to accelerate discovery and treatments in the neurosciences. That approach will continue to drive our research in the future.

Ngai also is director of the Functional Genomics Laboratory in the California Institute for Quantitative Biosciences, or QB3, a multi-campus initiative that fosters the development of biology as a quantitative, predictive science, with applications in health, energy and the environment. On the national level, Ngai has provided extensive service on NIH study sections, councils and steering groups, including as co-chair of the NIH BRAIN Initiative Cell Census Consortium Steering Group.

Ngai was born in New York City to Chinese immigrants who came to this country in 1947 to complete their medical training. He grew up with his two older sisters just outside of New York City in Teaneck, New Jersey. Science and medicine were the usual topics of conversation over dinner, as his parents were both faculty members at Columbia University College of Physicians and Surgeons, where his father a neuroscientist himself was professor and chair of anesthesiology and his mother a professor of pharmacology. He attended Pomona College in Claremont, California, and graduated with a bachelors degree in chemistry and zoology in 1980. His many honors include awards from the Sloan Foundation, Pew Charitable Trusts and McKnight Endowment Fund for Neuroscience.

Ngai said he will miss UC Berkeley, but is thrilled by the chance to head up one of the nations top biomedical priorities.

For the past 27 years, it has been such an amazing privilege for me to draw inspiration from the brilliant students, colleagues and staff at the worlds greatest public university, he said. I will take the lessons I learned here at Berkeley to my new role in enabling BRAIN Initiative investigators to unlock the secrets of the brain and lay new foundations for treating human brain disorders. The skys the limit.

Visit link:
Neuroscientist John Ngai named director of NIH BRAIN Initiative - UC Berkeley

The Future of Antivenom May Involve Mini Lab-Grown Snake Glands – Smithsonian.com

For the first time, scientists have grown miniature, venom-producing glands in the lab using coral snake embryos, according to a news study published in the journal Cell. Why might researchers want to create artificial venom glands, you ask?

The project was initially aimed to establish proof-of-concept more than anything else. Three graduate students at the Hubrecht Institute in the Netherlands had wondered: If lab-grown organs could be made that acted like mouse and human tissues, would it work for other animals, like reptiles?

Luckily, they were working in molecular geneticist Hans Clevers lab. Clevers is a prominent expert in stem cell research who pioneered research on the lab-grown organ imitationscalled organoidsa decade ago. Since then, researchers have created miniature human kidneys, livers, and brains in petri dishes.

On Fridays, members of the Clevers Lab are allowed to work on unstructured projects. To put their question to the test, Clevers students Yorick Post, Jens Puschhof, and Joep Beumer, would need a source of reptilian stem cells. As it happened, one of the researchers knew a guy: a snake breeder who could supply them with fertilized eggs, as STAT News Andrew Joseph reports.

They started with the egg of a Cape coral snake, removing the embryos venom glands and placing them in a dish. Then, they followed nearly the same protocol as they did with human cells, giving the cells ample supply of growth-inducing chemicals and storing them at a comfortable temperatureabout 89 degrees Fahrenheit, about ten degrees lower than the temperature used for human cells.

Soon, the plates held one-millimeter-long white blobs producing dangerous venom. With the organoids alive and well, the researchers told Clevers what theyd done, Leslie Nemo at Discover reports. If theyd told him beforehand, he would have told them it probably wouldnt work, Clevers tells the Atlantics Ed Yong. The chemicals they used were designed for human stem cells, and very little was known about stem cells in snakes. Still, the researchers were able to grow organoids from nine species of snakes.

Its a breakthrough, University of Costa Rica snake venom toxicologist Jos Mara Gutirrez, who was not involved in the study, tells Erin Malsbury at Science magazine. This work opens the possibilities for studying the cellular biology of venom-secreting cells at a very fine level, which has not been possible in the past, Malsbury says.

By looking closely at the organoids, Clevers team gained new insight into how multiple kinds of cells work together to produce the specific mixture of toxins and proteins that results in fully-developed venom.

Venomous snake bites kill between 81,000 and 138,000 people every year, according to the World Health Organization, and cause three times as many amputations and disabilities. The antidote to a snakebite is an antivenom, but each of thousands of venomous snakes have a different biteeach requiring a unique treatment. Even snakes of the same species can produce a slightly different venoms if they live in different regions.

Right now, antivenoms are produced using much the same process as was invented in the 19th century: a live snake is milked for its venom, that venom is injected into a horse. Horses have been used for antivenom production for years because of their docile nature and big veins, as Douglas Main wrote for Popular Mechanics in 2016. They are first injected with adjuvant, which stimulates their immune system to produce enough antibodies to neutralize the venom. Then, researchers take a sample of their blood and separate the antivenom from other component of blood, like plasma, in a centrifuge.

Clevers now hopes to create a bank of dozensand eventually thousandsof organoids from dangerous snakes and other reptiles that could aid in the effort to manufacture effective antivenoms.

"We could just sample one tissue once, and we have a source of [that snakes] venom for eternity," Clevers tells Discover.

Clevers is working with the Dutch biologist Freek Vonk, who he calls the Dutch Steve Irwin, to get samples of the snake species he hopes to include in the venom gland biobank. (Vonk works at Naturalis Biodiversity Center in Leiden and also has some excellent Dutch science tunes available on Spotify.)

With venom from organoids more easily available, the hope is to skip the horse in the antitoxin-production process. Researchers could instead use the organoid-produced venom to test an array of molecules for neutralizing abilities.

It will be interesting to see how the cost of producing venom using this system compares to the cost of purchasing venom milked from live snakes, since cost of antivenom is a key impediment to its wider use in countries where snakebite is a huge issue, like India and Nigeria, as Bangor University molecular zoologist Anita Malhotra tells the Atlantic.

Antivenoms made from lab-grown venom glands are likely years away, but the organoids could also be a big step for studying toxin production in more detail than previously possible. With the cells isolated from the rest of the snake, researchers might be able to look at how they can produce toxic chemicals without damaging themselves, for example.

Clevers tells Discover, We do the most interesting work when we dont have a proposal and just try things.

See the original post here:
The Future of Antivenom May Involve Mini Lab-Grown Snake Glands - Smithsonian.com

Dr. Edith Widder vouches for ocean conservation through exploration – The Wichitan

Colin StevensonMarine Biologist Edith Widder recounts her experiences from a Summer 2019 expedition where she recorded the first footage of a giant squid in US waters. Jan. 28.

Colin StevensonWidder closes with a quote from Jacques Cousteau before opening to questions from the audience. Jan. 28.

Colin StevensonAn audience member asks Widder about her experiences as a woman in a scientific field. In response, Widder recounts her mother as a role model and how she wasnt put into an engineering program due to her gender. Jan. 28.

Colin StevensonAfter an audience member asks about her view on environmentalism, Widder expands her earlier point that many environmentalists use a theme of fear, while she believes they should use hope to invoke better reactions. Jan. 28.

Colin StevensonEdith Widder explains the importance of bioluminescence research, referencing its use in cell biology studies as support. Jan. 28.

Colin StevensonAfter being asked about her 6-to-8-hour experiences in submersibles, Widder answers how cold and dark it seems, with potential bioluminescence always around her. Jan. 28.

Go here to see the original:
Dr. Edith Widder vouches for ocean conservation through exploration - The Wichitan

GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells – Benzinga

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions.

ATLANTA (PRWEB) January 29, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions. Trauma situations often do not allow for adequate blood typing due to time restrictions, so the GIOSTAR/HEAMGEN red blood cells address that need effectively.

"There are three main problems for blood transfusions," stated Dr. Anand Srivastava, Founder and Chairman of GIOSTAR. "First we have to match the blood type. Second, there's not enough blood available every single time. And third, when we transfer blood from one person to another person, there is always a chance of the transfer of disease."

Watch a feature interview with Dr. Anand Srivastava on The DM Zone with host Dianemarie Collins.

The World Health Organization (WHO) published the first detailed analysis on the global supply and demand for blood in October 2019 and found that 119 out of 195 countries do NOT have enough blood in their blood banks to meet hospital needs. In those nations, which include every country in central, eastern, and western sub-Saharan Africa, Oceania (not including Australasia), and south Asia are missing roughly 102,359,632 units of blood, according to World Health Organization (WHO) goals. While total blood supply around the world was estimated to be around 272 million units, in 2017, demand reached 303 million units. That means the world was lacking 30 million units of blood, and in the 119 countries with insufficient supply, that shortfall reached 100 million units.

The global market opportunity for GIOSTAR/HEAMGEN technology presents not only a profitable and scalable business opportunity but also a significant social and environmental impact. The global market is estimated to be at least $ 85 Billion/year.

GIOSTAR/HEAMGEN has identified early entry global markets to include Military, Trauma, Asia (replace Hepatitis C contaminated blood products), Africa (AIDS contaminated blood), Newborns, Thalassemia patients, Allosensitized sickle cell disease patients. South Sudan was found to have the lowest supply of blood, at 46 units per 100,000 people. In fact, the country's need for blood was deemed 75 times greater than its supply. In India, which had the largest absolute shortage, there was a shortfall of nearly 41 million units, with demand outstripping supply by over 400 percent. Strategic investments are needed in many low-income and middle-income countries to expand national transfusion services and blood management systems. Oncology is a major user of blood transfusion but if countries don't have the capacity to manage the bulk of oncology, it will limit complex surgery options.

GIOSTAR/HEAMGEN has acquired the exclusive license to the patent for the technique for stem cell proliferation from University of California San Diego (UCSD). The founding team of GIOSTAR/HEAMGEN is comprised of the scientists and clinicians who were involved in creating the Intellectual Property at UCSD and has already achieved PROOF OF CONCEPT - the optimized lab scale proliferation of mature red blood cells - at UCSD as part of their research.

GIOSTAR/HEAMGEN is currently looking for strategic partnerships (Contact Doug@DMProductionsLLC.com) to accelerate the development of donor-independent red blood cells manufacturing capabilities and advance the proof of concept work already done (patented) around the manufacture of safe, universal donor, human red blood cells. GIOSTAR/HEAMGEN will also develop a full automated proprietary bioreactor using robotic technology to produce abundant quantities of red blood cells with a goal for cost-effective commercialization of fresh, human, universal donor Red Blood Cells (RBCs).

ABOUT GIOSTAR

Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company's primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is world's leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a pioneer and a world-renowned authority in the field of Stem Cell Biology, Cancer and Gene therapy. Several governments and organizations including USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership, a group of esteemed scientists and clinicians have developed and established Stem Cell Therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe.

For the original version on PRWeb visit: https://www.prweb.com/releases/giostar_announces_medical_breakthrough_in_biotechnology_and_lifesciences_to_manufacture_abundant_safe_red_blood_cells_from_stem_cells/prweb16854975.htm

Go here to read the rest:
GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells - Benzinga

Validating the In-Silico Model for Toxicity Studies – News-Medical.net

Any experimental model or simulation must adhere to a series of validity requirements that confirm its applicability and reliability. This article will discuss the process by which in silico methods are verified before their use in preliminary toxicity studies.

Image Credit: Gorodenkoff/Shutterstock.com

In silico toxicology (IST), which is also denoted as computational toxicology, refers to the integration of modern computer technology with molecular biology to create a thorough risk assessment of new chemicals before the initiation of any cell or animal experiments. While IST methods are primarily used in the pharmaceutical industry during early drug development processes, they are also being investigated for their potential usefulness in assessing the toxicity of environmental chemicals. Some of the most widely applied IST methods include quantitative structure-activity relationships (QSAR) tests, pharmacophores, homology models, machine learning, data mining, network analysis tools and much more.

While the exercise of validating an experimental model can be performed by any individual or organization, the European Regulation on Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) requires that the manufacturer and/or importer of any chemical is responsible for its subsequent analysis and safety evaluation.

Legislative bodies REACH in the EU and the Organization for Economic Co-operation and Development (OECD) of the United States recognize both the lack of data that is currently available on both the toxicological and physicochemical properties of many chemicals, as well as the limited laboratory capacity that exists to measure these effects in real-time. To support the accurate use of new alternative methods of toxicity testing like IST, both REACH and the OECD have created general rules for the use of such methods.

Between 2002 and 2004, several international meetings were held to establish general rules that could be applied to the validation of QSAR and SAR techniques, both of which are widely used in academic, industrial and governmental institutions around the world. The conclusion of these meetings determined that for a QSAR method to be applied for regulatory purposes, it must adhere to five distinct criteria. Of these criteria include a defined endpoint, an unambiguous algorithm, a defined domain of applicability, appropriate measures of robustness, predictivity, and goodness-of-fit and, if possible, a mechanistic interpretation.

Once it has been established that a given IST method, such as a QSAR model, adheres to the OECD validation principles, it is required that all of the information gathered during its validation is documented in report formats such as the QSAR Model Reporting Format (QMRF). In addition to providing its scientific validity, researchers must also include what specific toxicological effect or mechanism is being predicted by the given IST model, as well as its version number, type of methodology, training set size and content.

Since many IST models often exhibit a limited applicability domain, which refers to the ability of these models to only make predictions that apply for a specific set of chemicals, this domain must be explicitly discussed before its use for any new chemical. To further increase the reliability of any IST prediction, it is recommended that researchers combine additional independent or complementary IST models in their review.

Raunio, H. (2011). In Silico Toxicology Non-Testing Methods. Frontiers of Pharmacology 2; 33. DOI: 10.3389/fphar.2011.00033.

Myatt, G. J., Ahlberg, E., Akahori, Y., Allen, D., Amberg, A., et al. (2018). In silico toxicology protocols. Regulatory Toxicology and Pharmacology 96; 1-17. DOI: 10.1016/j.yrtph.2018.04.014.

Tichy, M., & Rucki, M. (2009). Validation of QSAR models for legislative purposes. Interdisciplinary Toxicology 2(3); 184-186. DOI: 10.2478/v10102-009-0014-2.

Excerpt from:
Validating the In-Silico Model for Toxicity Studies - News-Medical.net

THSTI to hold basic course on Immunology – BSI bureau

Faridabad-based Translational Health Science and Technology Institute will be conducting the third edition of its basic course in Immunology from March 16 to 18.

Dr. Shiv Pillai, Professor, Harvard Medical School, Boston along with Dr. Dipankar Nandi from the Department of Biochemistry, Indian Institute of Science, Bengaluru will be covering the various topics of this domain.

The target audience for this course are Masters and PhD students, research associates and post-doctoral fellows, early career investigators. However, the course is open to other investigators also who would like to update on the knowledge of Immunology.

The last years course was attended by more than 250 participants comprising faculty members, research fellows and PhD students from institutes across the country. Researchers at Banaras Hindu University, AIIMS Delhi, PGIMER Chandigarh, SRM Sonipat, Tezpur University and others could attend by joining a live streaming session.

Continue reading here:
THSTI to hold basic course on Immunology - BSI bureau